Our ambitions are big and our product pipeline has never been stronger. We’re energized and inspired to apply science and our global resources to develop and deliver breakthrough therapies to people everywhere.To Our Investors Why Invest Financial Reports Events and Presentations Stock Information...
Product Pipeline Research Sites Products How Drugs are Made Branded vs. Generic Biologics & Biosimilars Commitment to Quality Global Supply Manufacturing Sites Medicine Safety Health Literacy Treatment Choices Partnering With Patients Tips for Patients Reporting Adverse Events Counterfeiting Product Safety Produc...
Our oncology pipeline doubled in size and is now armed with technologies that can help transform outcomes for patients. Pfizer has been a leading force in the treatment of cancer for more than two decades. When the world tells the story of how the lives of people with cancer were ...
The first-quarter 2022 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found on the Pfizer website. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “I am very proud of ...
The fourth-quarter 2022 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found atwww.pfizer.com. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “...
“As we look forward, we are confident in our future. With our clear strategic roadmap, a robust pipeline of potential innovative medicines and vaccines and a talented team laser-focused on execution, we believe we are on course to deliver significant shareholder value.” ...
近日读到一篇发表在Drug Discovery Today的综述文章《Reviving an R&D pipeline: a step change in the Phase II success rate》。该文介绍了Pfizer在2010年之后由于面临重磅品种专利悬崖的冲击,迫切需要提高研发成功率,故而在研发战略方面进行了若干变革。10年之后再看,Pfizer的II期成功率整体攀升,从19%提升到了53...
Great, thank you. A quick one on the pipeline and another on business development strategy. On the pipeline, I noticed in Phase 2, you've advanced the GIP antagonist. Is that something that you'll be continuing to share data on, particularly as a monotherapy? And do you have any efforts...
近日读到一篇发表在Drug Discovery Today的综述文章《Reviving an R&D pipeline: a step change in the Phase II success rate》。该文介绍了Pfizer在2010年之后由于面临重磅品种专利悬崖的冲击,迫切需要提高研发成功率,故而在研发战略方面进行了若干变革。10年之后再看,Pfizer的II期成功率整体攀升,从19%提升到了53...
In summary, 2022 was an outstanding year for our company, with our key growth drivers providing evidence of the depth and breadth of our portfolio. With the unprecedented wave of innovations expected to emerge from our scientific pipeline in the near term, potential business development activit...